FOXD1

Across TCGA pan-cancer cohorts, FOXD1 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of FOXD1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FOXD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FOXD1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

HNSC, COAD, and BLCA are the cancer types where FOXD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FOXD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+2.850	<.001	12	view →
COAD	Female	All	+1.369	<.001	11	view →
BLCA	Male	III,IV	+2.207	<.001	7	view →
LUSC	Male	All	+2.118	<.001	7	view →
THCA	All	All	−0.121	.001	7	view →
BRCA	All	II,III,IV	+0.915	<.001	6	view →
STAD	Male	All	+1.172	.001	4	view →
KIRC	Male	II,III,IV	−0.470	.014	4	view →
KICH	All	IV	+2.340	.021	3	view →
LUAD	All	All	+0.426	.007	3	view →
PAAD	All	All	+1.787	.012	2	view →
READ	Female	All	+1.472	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

FOXD1–HNSC

Open the HNSC breakdown →